Trial Profile
Synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in patients with Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Acamprosate/baclofen (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics; Therapeutic Use
- 29 Jul 2018 New trial record
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology